MEDIA RELEASE PR35406
NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and
Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
NEW YORK, July 15 /PRNewswire-AsiaNet/ --
NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-
term storage of adult stem cells for future medical need, was featured on CBS2 News, New York City's local
CBS station, on Monday evening July 13 and Tuesday morning July 14, 2009.
The segment "Go! New York" focused on the work of Dr. Christopher Centeno, a NeoStem consultant in
stem cell therapies for orthopedics, and featured the success of his innovative process that rapidly grows a
patient's own adult stem cells to treat a variety of musculoskeletal diseases. Interviews with Dr. Centeno at
the Centeno-Schultz Clinic near Denver, Colorado, and Dr. Robin Smith, CEO of NeoStem, were included.
Dr. Max Gomez, CBS2's medical expert, stated that autologous adult stem cells "have become the
cutting edge way to treat osteoarthritis of the knee, hip, and ankle and even back pain." He noted, "The
promise appears to be so great that more than 1,000 clinical trials are testing stem cell therapies" for
various conditions and "showing promising results for heart failure, diabetes, lupus and even macular
degeneration." He added, "That's why a company called NeoStem has begun banking people's own adult
stem cells -- now, before you need them."
NeoStem holds an exclusive royalty-bearing, perpetual and irrevocable license to use this technology of
Dr. Centeno and Regenerative Sciences, Inc. in the People's Republic of China (PRC) -- as announced on
May 11, 2009. The first such use is anticipated to be at the Wendeng Orthopedic Hospital in Shandong, one
of the leading specialist orthopedic hospitals in China. NeoStem, through its affiliate in China, is in the
process of implementing a plan to offer these orthopedic treatments in China through an initial network of
hospitals, of which Wendeng Hospital is the first. Dr. Centeno has been engaged to provide consulting
services, including selecting a suitable PRC partner hospital and assessing and training medical staff in
relation to the provision of stem cell therapies for orthopedics.
Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are very excited to be working
with Dr. Centeno to bring this therapy to China and believe that with Neostem's technology we can make
the therapy less invasive and in the future there will not be the need as there is today for stem cell
expansion." As Dr. Gomez pointed out, adult stem cell therapies are being successfully applied in an
increasing number of medical areas. In the past few months, NeoStem has obtained licenses to adult stem
cell applications in the therapeutic areas of wound-healing and skin rejuvenation as well as orthopedics.
These are the start of a pipeline of stem-cell-based regenerative medicine therapies that is a key element of
NeoStem's growth strategy in both the United States and China."
As stated in the Form 8-K of July 10, 2009: "The rationale behind NeoStem's expansion in China is to
accelerate stem cell therapy, research and development and creation of intellectual property position in an
environment that is more readily accepting of stem cell therapies. These initiatives will be led by U.S.
researchers and physicians in collaboration with experts in the PRC for each clinical indication to be
pursued. China has a large population with a rapidly growing middle and upper class who are becoming
focused on regenerative medicine and can afford such services. We believe that a collaboration involving
these two countries will create commercial, financial and scientific opportunities."
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling
people to donate and store their own (autologous) stem cells when they are young and healthy for their
personal use in times of future medical need. The Company has also entered into research and
development through the acquisition of a worldwide exclusive license to technology to identify and isolate
VSELs (very small embryonic-like stem cells), which have been shown to have several physical
characteristics that are generally found in embryonic stem cells and is pursuing other technologies to
advance its position in the field of stem cell tissue regeneration.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of
the date of this press release, and involve certain risks and uncertainties. The Company's actual results,
including its success, if any, in developing adult stem cell therapies could differ materially from those
anticipated in these forward-looking statements as a result of various factors. Factors that could cause
future results to materially differ from the recent results or those projected in forward-looking statements
include without limitation whether the Company's technologies will lead to successful therapeutic
treatments, the Company's ability to execute on its expansion plans in China and the "Risk Factors"
described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and
the Company's other periodic filings with the Securities and Exchange Commission. The Company's further
development is highly dependent on future medical and research developments and market acceptance,
which is outside its control.
CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
SOURCE: NeoStem, Inc.
CONTACT: NeoStem, Inc.,
Robin Smith,
Chief Executive Officer,
+1-212-584-4180, rsmith@neostem.com
(NBS)
NEWS 
